Aim: We decided to explore the effects of HCQ in combination with rosuvastatin on Lipid profile and HbA1c of patients with DKD.
Method: This is a real world study. T2DM (N=67, Age 52± 09), HbA1c ≥ 7%, with clinical evidence of DKD) were selected and alternatively divided into two groups with one group taking HCQ 400 mg in addition to their regular medications and other group without HCQ. Both groups were followed for next 3 months and changes in their serum creatinine(S.Cr), eGFR, Urine ACR, HbA1C,FPG, PPG, LDL, HDL, TG were noted. All patients were on DPP-4i and metformin along with short acting insulin with dosage modified according to daily insulin need and changes in insulin requirement with changing renal function for at least 3months prior to the study.
Results: TG levels were reduced by 25.01% and 10.69% in the HCQ and Non - HCQ Gr respectively, LDL-cholesterol levels were reduced in HCQ while it increase in the Non HCQ. TC declined more with HCQ and significant increase in HDL. SCr. was decline in HCQ Gr, while it increased in Non-HCQ. Similarly, eGFR was rising in the HCQ and decreased in the Non-HCQ. Also, Urinary ACR decreased with HCQ, but continued to increase in Non-HCQ.
Conclusion: Therefore, we concluded that HCQ can be an option in patients of early stages of DKD in such patients and it may be combined with rosuvastatin for better lowering of lipid levels and better control of HbA1c.
A. Baidya: None. S. Guha: None. S. Kumar: None. A. Shankar: None.